Check-Cap Ltd Asset Resilience Ratio
Check-Cap Ltd asset resilience ratio. Check-Cap Ltd (7CC) has an Asset Resilience Ratio of 2.90% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 7CC cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Check-Cap Ltd (2018–2025)
Asset resilience ratio of Check-Cap Ltd from 2018 to 2025. This chart shows how Check-Cap Ltd's Asset Resilience Ratio has changed over time. Read debt load of Check-Cap Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Check-Cap Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Check-Cap Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €217.00K | 2.9% |
| Total Liquid Assets | €217.00K | 2.90% |
Asset Resilience Insights
- Limited Liquidity: Check-Cap Ltd maintains only 2.90% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Check-Cap Ltd Industry Peers by Asset Resilience Ratio
Compare Check-Cap Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA |
Diagnostics & Research | 15.15% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Check-Cap Ltd Asset Resilience Ratio by Year (2018–2025)
Check-Cap Ltd asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Check-Cap Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.90% | €217.00K ≈ $253.70K |
€7.49 Million ≈ $8.75 Million |
-60.71pp |
| 2023-12-31 | 63.60% | €15.91 Million ≈ $18.60 Million |
€25.02 Million ≈ $29.25 Million |
-19.16pp |
| 2022-12-31 | 82.76% | €37.61 Million ≈ $43.97 Million |
€45.44 Million ≈ $53.13 Million |
+37.66pp |
| 2021-12-31 | 45.10% | €25.10 Million ≈ $29.35 Million |
€55.66 Million ≈ $65.07 Million |
-6.22pp |
| 2020-12-31 | 51.32% | €10.08 Million ≈ $11.78 Million |
€19.64 Million ≈ $22.96 Million |
-- |
| 2019-12-31 | 0.00% | €0.00 ≈ $0.00 |
€9.43 Million ≈ $11.02 Million |
-- |
| 2018-12-31 | 36.56% | €5.64 Million ≈ $6.60 Million |
€15.44 Million ≈ $18.05 Million |
-- |
About Check-Cap Ltd
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology for the detection of precancerous colorectal polyps. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.